Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.

Trial Profile

Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Nov 2018 Status changed to discontinued as per PI's request
    • 31 Aug 2018 Biomarkers information updated
    • 07 May 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top